Skip to main content

Table 1 Characteristics of the participant enrollments in the current study and that of the parent trial

From: Advanced biological age is associated with improved antibody responses in older high-dose influenza vaccine recipients over four consecutive seasons

 

Current subset (N = 292)

Parent trial (N = 612)

Age

76 (7.11)

76 (7.4)

Sex

Female

190 (65.1%)

410 (67.0%)

Male

102 (34.9%)

202 (33.0%)

BMI (kg/m2)

28 (4.72)

28 (4.87)

Missing

1 (0.3%)

3 (0.5%)

CMV serostatus

Negative

130 (44.5%)

287 (46.9%)

Positive

162 (55.5%)

325 (53.1%)

Frailty Index

0.11 (0.0708)

0.11 (0.0734)

Missing

0 (0%)

2 (0.3%)

Dose

Standard

145 (49.7%)

316 (51.6%)

High

147 (50.3%)

296 (48.4%)

Site

HSNRI

184 (63.0%)

356 (58.2%)

UCHC

108 (37.0%)

256 (41.8%)

Year

2014/2015

58 (19.9%)

106 (17.3%)

2015/2016

79 (27.1%)

175 (28.6%)

2016/2017

83 (28.4%)

174 (28.4%)

2017/2018

72 (24.7%)

157 (25.7%)

  1. Continuous data is summarized as the mean (standard deviation), whereas categorical data is the count (frequency)